| 嵌合抗原受体修饰T细胞治疗前列腺癌的研究进展 |
| |
| 引用本文： | 尤祥云,向振东,易成,张满,喻俊峰△. 嵌合抗原受体修饰T细胞治疗前列腺癌的研究进展[J]. 天津医药, 2020, 48(10): 1020-1024. DOI: 10.11958/20200611 |
| |
| 作者姓名： | 尤祥云 向振东 易成 张满 喻俊峰△ |
| |
| 作者单位： | 1三峡大学人民医院泌尿外科（邮编443000）；2湖北省宜昌市第一人民医院泌尿外科 |
| |
| 基金项目： | 宜昌市财政科技专项基金资助项目（A20-2-021） |
| |
| 摘 要： | 摘要：嵌合抗原受体修饰T细胞（CAR-T）是近年来免疫治疗的热点，在血液系统疾病的治疗中取得了显著的临床疗效。目前，CAR-T在前列腺癌（PCa）治疗的研究中也取得了较大进展，其中以前列腺特异性膜抗原（PSMA）和前列腺干细胞抗原（PSCA）为靶点的CAR-T治疗进展较快，其可显著抑制肿瘤细胞生长，一定程度地延缓疾病进展。本文综述了前列腺肿瘤相关抗原（TAA）在前列腺癌CAR-T治疗中的最新研究进展，并对CAR-T在前列腺癌治疗中的挑战予以简要探讨，以期为临床提供参考。
|
| 关 键 词： | 前列腺肿瘤 免疫治疗 嵌合抗原受体修饰T细胞 前列腺特异性膜抗原 前列腺干细胞抗原 |
| 收稿时间： | 2020-03-21 |
| 修稿时间： | 2020-07-30 |
Advances in the treatment of prostate cancer by chimeric antigen receptor modified T cells |
| |
| YOU Xiang-yun,XIANG Zhen-dong,YI Cheng,ZHANG Man,YU Jun-feng△. Advances in the treatment of prostate cancer by chimeric antigen receptor modified T cells[J]. Tianjin Medical Journal, 2020, 48(10): 1020-1024. DOI: 10.11958/20200611 |
| |
| Authors: | YOU Xiang-yun XIANG Zhen-dong YI Cheng ZHANG Man YU Jun-feng△ |
| |
| Affiliation: | 1 Department of Urology, the People’s Hospital of China Three Gorges University, Yichang 443000, China; 2 Department of Urology, the First People’s Hospital of Yichang |
| |
| Abstract: | Abstract：The research of chimeric antigen receptor modification T cells (CAR-T) is a hotspot in immunotherapy in recent years, which has achieved remarkable clinical efficacy in the treatment of hematological diseases. At present, CAR-T has also made great progress in the treatment of prostate cancer (PCa). CAR-T therapy targeting prostate-specific membrane antigen (PSMA) and prostate-stem cell antigen (PSCA) has made rapid progresses, which can significantly inhibit tumor cell growth and delay disease progression in a certain extent. This article reviewed the recent clinical research progress of prostate cancer associated antigen (TAA) in the treatment of prostate cancer with CAR-T, and briefly discussed the challenges of CAR-T in the treatment of prostate cancer for better clinical application. |
| |
| Keywords: | prostatic neoplasms immunotherapy chimeric antigen receptor modified T cell prostate-specific membrane antigen prostate-stem cell antigen |
|
| 点击此处可从《天津医药》浏览原始摘要信息 |
|
点击此处可从《天津医药》下载全文 |
